THDB(SH:600867)2023-04-26 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥665,357,856.54, representing a decrease of 25.03% compared to the same period last year[4] - The net profit attributable to shareholders for Q1 2023 was ¥250,436,583.32, down 69.87% year-on-year[4] - Basic earnings per share for Q1 2023 were ¥0.13, a decrease of 69.63% year-on-year[5] - The company reported a significant decline in investment income by 97.34%, primarily due to the previous year's gains from the sale of shares in Xiamen Te Bao Biological Engineering Co., Ltd.[9] - The net profit attributable to the parent company decreased by 55.78%, mainly due to price reductions in biological products following centralized procurement[9] - Total revenue for Q1 2023 was approximately ¥665.36 million, a decrease of 25% compared to ¥887.48 million in Q1 2022[18] - Net profit for Q1 2023 was approximately ¥250.67 million, a decline of 70% from ¥831.18 million in Q1 2022[19] - The total profit for Q1 2023 was approximately ¥291.34 million, a decrease of 70% compared to ¥979.84 million in Q1 2022[19] Cash Flow and Assets - The net cash flow from operating activities was ¥156,380,702.45, reflecting a decline of 55.78% compared to the previous year[4] - Cash flow from operating activities for Q1 2023 was approximately ¥156.38 million, down 56% from ¥353.63 million in Q1 2022[21] - The cash and cash equivalents at the end of the period amounted to 858,223,602.54 CNY, down from 1,039,713,134.29 CNY year-over-year[22] - The net increase in cash and cash equivalents for the quarter was 70,160,771.56 CNY, compared to 174,673,588.90 CNY in the previous period[22] - The company reported cash and cash equivalents of CNY 858,223,602.54, an increase from CNY 788,062,830.98 in the previous year, representing a growth of about 8.89%[14] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,998,080,337.53, an increase of 3.67% from the end of the previous year[5] - The company's current assets totaled CNY 2,228,093,885.84, up from CNY 2,056,412,954.78 in the previous year, indicating an increase of about 8.34%[14] - The total liabilities of the company were CNY 200,011,583.14, slightly down from CNY 200,740,113.58 as of December 31, 2022, showing a decrease of about 0.36%[16] - The equity attributable to shareholders reached CNY 6,792,832,969.04, an increase from CNY 6,544,263,425.28 at the end of 2022, marking a growth of approximately 3.79%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 89,451[10] - The largest shareholder, Dongbao Industrial Group Co., Ltd., held 29.68% of the shares, with 510,209,472 shares pledged[10] Research and Development - The company has maintained a strong focus on research and development, with significant investments in innovative drug formulations and technologies[15] - Research and development expenses for Q1 2023 were approximately ¥27.83 million, a slight decrease from ¥29.33 million in Q1 2022[18] Future Outlook - The company plans to expand its market presence and invest in new product development to enhance its competitive edge in the pharmaceutical industry[15] - The management expressed optimism about future growth prospects, citing ongoing projects and potential market opportunities in the pharmaceutical sector[15] Investment Activities - The net cash flow from investing activities was -86,189,926.05 CNY, compared to -137,608,286.47 CNY in the previous period[22] - The company reported a significant decrease in investment payments, totaling 58,000,000.00 CNY compared to 599,000,000.00 CNY in the previous period[22]